VX-702

Catalog No.S6005

VX-702 Chemical Structure

Molecular Weight(MW): 404.3

VX-702 is a highly selective inhibitor of p38α MAPK, 14-fold higher potency against the p38α versus p38β. Phase 2.

Size Price Stock Quantity  
In DMSO USD 64 In stock
USD 70 In stock
USD 110 In stock
USD 370 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

2 Customer Reviews

  • Reduction of IL-10 expression due to p38 inhibition is observed also in CpG-stimulated B cells and using VX-702. B cells were pre-treated with 10 uM of VX-702 for 1 h and stimulated with LPS or CpG for 24 or 48 h. Bar graphs indicate mean (±SEM) IL-10 concentrations at 48 h from n = 4 (LPS) and n = 3 (CpG) experiments. Significant differences against the no inhibitor condition were calculated using a paired Student's t-test and indicated as follows: *p < 0.05, ***p < 0.001.

    Mol Immunol 2014 62(2), 266-76. VX-702 purchased from Selleck.

     Bone marrow derived macrophages were pre-treated with the indicated concentrations of VX702 for 1h prior to LPS treatment (100 ng/ml).  TNF-a production was analyzed 24h later.

    Lee lay hoon from National University of Singapore. VX-702 purchased from Selleck.

Purity & Quality Control

Choose Selective p38 MAPK Inhibitors

Biological Activity

Description VX-702 is a highly selective inhibitor of p38α MAPK, 14-fold higher potency against the p38α versus p38β. Phase 2.
Features Highly selective, orally active inhibitor of p38 MAPK.
Targets
p38α [1]
(Cell-free assay)
4 nM-20 nM
In vitro

Pre-incubation of platelets with VX-702 (1 μM) completely or partially inhibits p38 activation (IC50 4 to 20 nM) induced by platelet agonists including thrombin, SFLLRN, AYPGKF, U46619 and collagen. VX-702 shows no effect on platelet aggregation induced by any of the p38 MAPK agonists in the presence or absence of anti-platelet therapies. [1] VX-702 inhibits the production of IL-6, IL-1β and TNFα (IC50 = 59, 122 and 99 ng/mL, respectively) in a dose-dependent manner. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HOP-62 cell MWfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NWjYV3J[UW6qaXLpeIlwdiCxZjDoeY1idiCKT2CtOlIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjBzNUSzJO69VQ>? NUXzUIFtW0GQR1XS
human NCI-H720 cell NFz2SW5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1L1fGlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi3NlAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjBzNkiyJO69VQ>? M3LTUXNCVkeHUh?=
JVM-2 cell MlnXS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NVjIbIlRUW6qaXLpeIlwdiCxZjDoeY1idiCMVl2tNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvODh|IN88US=> M1fQXHNCVkeHUh?=
human NCI-H69 cell NVrTNlk1T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYfJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KNkmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlA6QTRzIN88US=> NYD2eVFVW0GQR1XS
human BV-173 cell MkLOS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3vqSmlvcGmkaYTpc44hd2ZiaIXtZY4hSlZvMUezJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yOTN6NjFOwG0> NWrNUpllW0GQR1XS
human KU812 cell M1\VZ2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWfJcohq[mm2aX;uJI9nKGi3bXHuJGtWQDF{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6xNlQ5QCEQvF2= MUjTRW5ITVJ?
human DU-145 cell NX3tOnk4T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NWfzcVlbUW6qaXLpeIlwdiCxZjDoeY1idiCGVT2xOFUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjF2NUW0JO69VQ>? Mkf2V2FPT0WU
KARPAS-45 cell NFrxfFZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Moi1TY5pcWKrdHnvckBw\iCqdX3hckBMSVKSQWOtOFUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjF2OEK2JO69VQ>? NUHncWl1W0GQR1XS
human AGS cell NWXkWnQ3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MnG5TY5pcWKrdHnvckBw\iCqdX3hckBCT1NiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkG1NlUyKM7:TR?= MUXTRW5ITVJ?
human MOLT-13 cell MVHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NUfE[mRKUW6qaXLpeIlwdiCxZjDoeY1idiCPT1zUMVE{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5zNUm4NUDPxE1? MkHuV2FPT0WU
human NCI-H209 cell NYXEWmV3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHuzepJKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlA6KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5zN{W4JO69VQ>? M3jVPXNCVkeHUh?=
human CTV-1 cell NHrOcFZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M{[0bWlvcGmkaYTpc44hd2ZiaIXtZY4hS1SYLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlE5Ozh7IN88US=> NYTxVXhPW0GQR1XS
LU-139 cell M{i0[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYPJcohq[mm2aX;uJI9nKGi3bXHuJGxWNTF|OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVk1OzVizszN NY[2cJV[W0GQR1XS
ML-2 cell MmLtS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M{\tXWlvcGmkaYTpc44hd2ZiaIXtZY4hVUxvMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNlI3PjFizszN MkjrV2FPT0WU
human K5 cell NIiyfo5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MUTJcohq[mm2aX;uJI9nKGi3bXHuJGs2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5{MkmxO{DPxE1? MV3TRW5ITVJ?
human SBC-1 cell MWLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NUjXTmpxUW6qaXLpeIlwdiCxZjDoeY1idiCVQlOtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjN4MjFOwG0> NGC5XmFUSU6JRWK=
human COR-L88 cell M1TiXWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MorDTY5pcWKrdHnvckBw\iCqdX3hckBEV1JvTEi4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{OzR6IN88US=> MVHTRW5ITVJ?
human KY821 cell M{DUNmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MUfJcohq[mm2aX;uJI9nKGi3bXHuJGt[QDJzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6zPVYxOyEQvF2= Mn\DV2FPT0WU
human HCC2218 cell NIP0TpFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1zaWmlvcGmkaYTpc44hd2ZiaIXtZY4hUEOFMkKxPEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPDl5Mkig{txO M3\zdXNCVkeHUh?=
human ECC10 cell MmXhS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NF;wdGtKdmirYnn0bY9vKG:oIHj1cYFvKEWFQ{GwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE43PTN6OTFOwG0> NXjp[mpCW0GQR1XS
human EW-3 cell Ml3VS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXjJcohq[mm2aX;uJI9nKGi3bXHuJGVYNTNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLk[2OlEyKM7:TR?= NVTydZRlW0GQR1XS
human EW-18 cell MlmyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NYnP[GlMUW6qaXLpeIlwdiCxZjDoeY1idiCHVz2xPEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPzR4N{mg{txO NVXWNoE{W0GQR1XS
human UACC-257 cell MVPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHfje5ZKdmirYnn0bY9vKG:oIHj1cYFvKFWDQ1OtNlU4KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS5{MEOyOkDPxE1? MWTTRW5ITVJ?
human G-361 cell MWTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Ml;aTY5pcWKrdHnvckBw\iCqdX3hckBINTN4MTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuOFk2OTlizszN MUXTRW5ITVJ?
human HMV-II cell MWfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGfsOYhKdmirYnn0bY9vKG:oIHj1cYFvKEiPVj3JTUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPzdzOESg{txO M1fwdXNCVkeHUh?=
human DEL cell MX7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MonDTY5pcWKrdHnvckBw\iCqdX3hckBFTUxiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkKwO|A1KM7:TR?= NFXlVmtUSU6JRWK=
human IGROV-1 cell M{XDVGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MX\Jcohq[mm2aX;uJI9nKGi3bXHuJGlIWk:YLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlQ{OTh6IN88US=> NE\RPGxUSU6JRWK=
human SK-OV-3 cell NVLmNZRsT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MUDJcohq[mm2aX;uJI9nKGi3bXHuJHNMNU:YLUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlYyPjl5IN88US=> MVPTRW5ITVJ?
human LAMA-84 cell MYLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MUPJcohq[mm2aX;uJI9nKGi3bXHuJGxCVUFvOESgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlcyOjh2IN88US=> MWfTRW5ITVJ?
human NCI-H510A cell MWnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MlHtTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEWxNGEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjl{NUK2JO69VQ>? MXvTRW5ITVJ?
human CP66-MEL cell NEHu[YFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1LaXmlvcGmkaYTpc44hd2ZiaIXtZY4hS1B4Nj3NSWwh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjl|NUW5JO69VQ>? M3rhT3NCVkeHUh?=
human HAL-01 cell NH7B[WxIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnnETY5pcWKrdHnvckBw\iCqdX3hckBJSUxvMEGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlI4QTF6IN88US=> M1m0dnNCVkeHUh?=
human RS4-11 cell  MVnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXXIeWU4UW6qaXLpeIlwdiCxZjDoeY1idiCUU{StNVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjdyNUezJO69VQ>? MULTRW5ITVJ?
human RPMI-8226 cell NGPR[5JIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NH\XZ2ZKdmirYnn0bY9vKG:oIHj1cYFvKFKSTVmtPFIzPiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTNwOEKzO|Yh|ryP MoHKV2FPT0WU
human NCI-H82 cell MUXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Ml;DTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEiyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{45QTNyNTFOwG0> NFLsb2VUSU6JRWK=
human NY cells NIW5fHJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NHm1NY1KdmirYnn0bY9vKG:oIHj1cYFvKE6\IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND6yO|Y{PyEQvF2= M1;MNHNCVkeHUh?=
human MDA-MB-361 cell NFP1e4pIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NEjFSWtKdmirYnn0bY9vKG:oIHj1cYFvKE2GQT3NRk0{PjFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12LkSzNVU5KM7:TR?= NWHDUFBJW0GQR1XS
human MOLT-4 cell MkXPS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFzaWYhKdmirYnn0bY9vKG:oIHj1cYFvKE2RTGStOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvQTlzOUOg{txO NGnQTYdUSU6JRWK=
human DU-4475 cell Mlf0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mk\uTY5pcWKrdHnvckBw\iCqdX3hckBFXS12NEe1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU4xPTV4NTFOwG0> MoTQV2FPT0WU
human ESS-1 cell Ml63S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1TwUGlvcGmkaYTpc44hd2ZiaIXtZY4hTVOVLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlI6OTd7IN88US=> M{XmUnNCVkeHUh?=
human NCI-H1299 cell MX7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVLJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMUK5PUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPTNyM{Og{txO NXjXWmsxW0GQR1XS
human COLO-684 cell NIPXOGlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mn3rTY5pcWKrdHnvckBw\iCqdX3hckBEV0yRLU[4OEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPThzNkWg{txO NYP0b4JtW0GQR1XS
human MV-4-11 cell NX7s[HJYT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4rIdGlvcGmkaYTpc44hd2ZiaIXtZY4hVVZvND2xNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPzFzOUmg{txO M2K0UHNCVkeHUh?=
human D-542MG cell MWjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mlv6TY5pcWKrdHnvckBw\iCqdX3hckBFNTV2Ml3HJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok4{QTJ5MjFOwG0> NVLlO2RDW0GQR1XS
human A4-Fuk cell NU\UfFVET3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFLvfVRKdmirYnn0bY9vKG:oIHj1cYFvKEF2LV\1b{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVYvPDN4NkKg{txO MUHTRW5ITVJ?
human HL-60 cell NU\4W|g4T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NX;nbYl3UW6qaXLpeIlwdiCxZjDoeY1idiCKTD22NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVcvPTJ{MUKg{txO NXHFVI85W0GQR1XS
human NCI-H526 cell NGTI[VFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NYjLdVRxUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFUzPiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTdwNUm4NFEh|ryP MlHUV2FPT0WU
human L-363 cell M4TTUWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NUS2NZRHUW6qaXLpeIlwdiCxZjDoeY1idiCOLUO2N{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVcvPzl{NUKg{txO MYTTRW5ITVJ?
human A388 cell MXTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3TlZmlvcGmkaYTpc44hd2ZiaIXtZY4hSTN6ODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUeuPFA{QDRizszN MoLzV2FPT0WU
human MS-1 MkTZS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmXkTY5pcWKrdHnvckBw\iCqdX3hckBOWy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nz64N|Q3PSEQvF2= Ml3ZV2FPT0WU
human JAR cell NH7TN2pIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYjJcohq[mm2aX;uJI9nKGi3bXHuJGpCWiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTdwOES5NlMh|ryP MWLTRW5ITVJ?
human TI-73 cell NVXGT4RZT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MknFTY5pcWKrdHnvckBw\iCqdX3hckBVUS15MzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUiuNFYzOiEQvF2= M4n4cXNCVkeHUh?=
human CTB-1 cell MoHVS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MorsTY5pcWKrdHnvckBw\iCqdX3hckBEXEJvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUiuNVc5OjVizszN NFr2UHVUSU6JRWK=
human SK-NEP-1 cell M4rlXGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXvBfHNyUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3OSXAuOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFzLkOwN|gh|ryP MoXwV2FPT0WU
human HT-29 cell MV\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3fPdWlvcGmkaYTpc44hd2ZiaIXtZY4hUFRvMkmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xN{46OTFzIN88US=> MmrnV2FPT0WU
human NCI-H1092 cell NX7Q[nVTT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVTJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMUC5NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVE1NjNzODFOwG0> MYXTRW5ITVJ?
human KMOE-2 cell MWnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MWTJcohq[mm2aX;uJI9nKGi3bXHuJGtOV0VvMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUG0MlYyPzhizszN MXTTRW5ITVJ?
human EM-2 cell NEi1T3BIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M{fPcGlvcGmkaYTpc44hd2ZiaIXtZY4hTU1vMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUG1MlI5PDFizszN MkO0V2FPT0WU
human RT-112 cell NFvKWpZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NYHEOWFJUW6qaXLpeIlwdiCxZjDoeY1idiCUVD2xNVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yPS5|OUi0JO69VQ>? M3TGR3NCVkeHUh?=
human DB cell NH7mcVdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NUjxdpZSUW6qaXLpeIlwdiCxZjDoeY1idiCGQjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUG1Mlg2OTNizszN NY\VUnV[W0GQR1XS
human NCI-H1770 cell NUf5cXJQT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MnTSTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG3O|Ah[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigQ>? MorFV2FPT0WU
human CAL-54 cell MlfCS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGDke4RKdmirYnn0bY9vKG:oIHj1cYFvKEODTD21OEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVE3Njd|IN88US=> M1voZXNCVkeHUh?=
human NB14 cell Mmq3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGnGS3ZKdmirYnn0bY9vKG:oIHj1cYFvKE6EMUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xO{43Ozl3IN88US=> M1XTfHNCVkeHUh?=
human RPMI-7951 cell MVLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFvwfW9KdmirYnn0bY9vKG:oIHj1cYFvKFKSTVmtO|k2OSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTF7LkG3PFMh|ryP M2S0XnNCVkeHUh?=
human T47D cell M4ToSWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{PZNWlvcGmkaYTpc44hd2ZiaIXtZY4hXDR5RDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKxMlIzPDNizszN MmfvV2FPT0WU
human A549 cell M1e5PGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1LUdmlvcGmkaYTpc44hd2ZiaIXtZY4hSTV2OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKxMlI5OTFizszN NFPHeldUSU6JRWK=
human A2780 cell NVnhRXFRT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MkHPTY5pcWKrdHnvckBw\iCqdX3hckBCOjd6MDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKxMlgzOjVizszN NEHH[|BUSU6JRWK=
human SK-MEL-24 cell MoPSS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NW\oeHVpUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3NSWwuOjRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|Mz6wN|EyKM7:TR?= M1P3NHNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo The half-life of VX-702 is 16 to 20 hours, with a median clearance of 3.75 L/h and a volume of distribution of 73 L/kg. Both AUC and Cmax values are dose proportional for VX-702, which is predominantly cleared renally. [2] VX-702 (at a dose of 0.1 mg/kg twice daily) has an equivalent effect as that of methotrexate (0.1 mg/kg). In addition, VX-702 (5 mg/kg twice daily) also has an equivalent effect as prednisolone (10 mg/kg once daily), as measured by percentage inhibition of wrist joint erosion and inflammation score. [3] VX-702 selectively inhibits activation of p38 MAPK after ischemia with no effects on ERKs and JNKs. The MI/AAR ratio is significantly reduced in the 50 mg/kg group compared with the 5 mg/kg and vehicle groups.[4]

Protocol

Solubility (25°C)

In vitro DMSO 81 mg/mL (200.34 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
30% PEG400+0.5% Tween80+5% propylene glycol
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 404.3
Formula

C19H12F4N4O2

CAS No. 745833-23-2
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00395577 Completed Rheumatoid Arthritis Vertex Pharmaceuticals Incorporated November 2006 Phase 2
NCT00205478 Completed Rheumatoid Arthritis Vertex Pharmaceuticals Incorporated June 2005 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

p38 MAPK Signaling Pathway Map

p38 MAPK Inhibitors with Unique Features

Related p38 MAPK Products

Tags: buy VX-702 | VX-702 supplier | purchase VX-702 | VX-702 cost | VX-702 manufacturer | order VX-702 | VX-702 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID